Int Neurourol J.  2021 May;25(Suppl 1):S8-18. 10.5213/inj.2142166.083.

Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children

• Moon JU
• Cho KO

• KMID: 2516588
• DOI: http://doi.org/10.5213/inj.2142166.083

Abstract

Epileptic encephalopathy (EE) is a devastating pediatric disease that features medically resistant seizures, which can contribute to global developmental delays. Despite technological advancements in genetics, the neurobiological mechanisms of EEs are not fully understood, leaving few therapeutic options for affected patients. In this review, we introduce the most common EEs in pediatrics (i.e., Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome) and their molecular mechanisms that cause excitation/inhibition imbalances. We then discuss some of the essential molecules that are frequently dysregulated in EEs. Specifically, we explore voltage-gated ion channels, synaptic transmission-related proteins, and ligand-gated ion channels in association with the pathophysiology of Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome. Finally, we review currently available antiepileptic drugs used to treat seizures in patients with EEs. Since these patients often fail to achieve seizure relief even with the combination therapy, further extensive research efforts to explore the involved molecular mechanisms will be required to develop new drugs for patients with intractable epilepsy.

Keyword

Intractable epilepsy; Antiepileptic drugs; Ohtahara syndrome; Dravet syndrome; Lennox-Gastaut syndrome